DNA methylation analysis of SFRP2, GATA4/5, NDRG4 and VIM for the detection of colorectal cancer in fecal DNA

Lu,Hongna; Huang,Shiliang; Zhang,Xie; Wang,Danping; Zhang,Xuesong; Yuan,Xiaogang; Zhang,Qiubo; Huang,Zhigang

doi:10.3892/ol.2014.2413

DNA methylation analysis of SFRP2, GATA4/5, NDRG4 and VIM for the detection of colorectal cancer in fecal DNA

Authors:
- Hongna Lu
- Shiliang Huang
- Xie Zhang
- Danping Wang
- Xuesong Zhang
- Xiaogang Yuan
- Qiubo Zhang
- Zhigang Huang
View Affiliations

Affiliations: Ningbo Medical Center, Li Huili Hospital, Ningbo, Zhejiang 315040, P.R. China, Medical School of Ningbo University, Ningbo, Zhejiang 315211, P.R. China
Published online on: August 4, 2014 https://doi.org/10.3892/ol.2014.2413
Pages: 1751-1756

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aberrantly methylated genes are increasingly being established as biomarkers for the detection of colorectal cancer (CRC). In the present study, the methylation levels of the secreted frizzled‑related protein gene 2 (SFRP2), GATA binding protein 4/5 (GATA4/5), N‑Myc downstream‑regulated gene 4 (NDRG4) and vimentin (VIM) promoters were evaluated for their use as markers in the noninvasive detection of CRC. Methylation‑specific polymerase chain reaction was performed to analyze promoter CpG methylation of SFRP2, GATA4/5, NDRG4 and VIM in the fecal DNA of 56 patients with CRC and 40 individuals exhibiting normal colonoscopy results. Promoter methylation levels of SFRP2, GATA4/5, NDRG4 and VIM in CRC patients were 57.1% (32/56), 42.9% (24/56), 83.9% (47/56), 28.6% (16/56) and 41.1% (23/56), respectively. Furthermore, the specificity of the genes were 90.0% (4/40), 95.0% (2/40), 82.5% (7/40), 97.5% (4/40) and 85.0% (6/40), respectively. The overall sensitivity of detection for fecal DNA with at least one methylated gene was 96.4% (54/56) in CRC patients. By contrast, only 14 of the 40 normal individuals exhibited methylated DNA in the aforementioned promoter regions. Methylation of the SFRP2, GATA4/5, NDRG4 and VIM promoters in fecal DNA is associated with the presence of colorectal tumors. Therefore, the detection of aberrantly methylated DNA in fecal samples may present a promising, noninvasive screening method for CRC.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012.
2	Jenkinson F and Steele RJ: Colorectal cancer screening-methodology. Surgeon. 8:164–171. 2010.
3	Kim MS, Lee J and Sidransky D: DNA methylation markers in colorectal cancer. Cancer Metastasis Rev. 29:181–206. 2010.
4	Kondo Y and Issa JP: Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 23:29–39. 2004.
5	Baek YH, Chang E, Kim YJ, et al: Stool methylation-specific polymerase chain reaction assay for the detection of colorectal neoplasia in Korean patients. Dis Colon Rectum. 52:1452–1459; discussion 1459–1463. 2009.
6	Leung WK, To KF, Man EP, et al: Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am J Gastroenterol. 102:1070–1076. 2007.
7	Petko Z, Ghiassi M, Shuber A, et al: Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res. 11:1203–1209. 2005.
8	Ausch C, Kim YH, Tsuchiya KD, et al: Comparative analysis of PCR-based biomarker assay methods for colorectal polyp detection from fecal DNA. Clin Chem. 55:1559–1563. 2009.
9	Abbaszadegan MR, Tavasoli A, Velayati A, et al: Stool-based DNA testing, a new noninvasive method for colorectal cancer screening, the first report from Iran. World J Gastroenterol. 13:1528–1533. 2007.
10	Frommer M, McDonald LE, Millar DS, et al: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA. 89:1827–1831. 1992.
11	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009.
12	Vernon SW: Participation in colorectal cancer screening: a review. J Natl Cancer Inst. 89:1406–1422. 1997.
13	Winawer S, Fletcher R, Rex D, et al; Gastrointestinal Consortium Panel. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 124:544–560. 2003.
14	Ahlquist DA and Shuber AP: Stool screening for colorectal cancer: evolution from occult blood to molecular markers. Clin Chim Acta. 315:157–168. 2002.
15	Ahlquist DA, Skoletsky JE, Boynton KA, et al: Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology. 119:1219–1227. 2000.
16	Wu GH, Wang YM, Yen AM, et al: Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries. BMC Cancer. 6:1362006.
17	Luo YX, Chen DK, Song SX, et al: Aberrant methylation of genes in stool samples as diagnostic biomarkers for colorectal cancer or adenomas: a meta-analysis. Int J Clin Pract. 65:1313–1320. 2011.
18	Suzuki H, Gabrielson E, Chen W, et al: A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet. 31:141–149. 2002.
19	Müller HM, Oberwalder M, Fiegl H, et al: Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet. 363:1283–1285. 2004.
20	Huang Z, Li L and Wang J: Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci. 52:2287–2291. 2007.
21	Hellebrekers DM, Lentjes MH, van den Bosch SM, et al: GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res. 15:3990–3997. 2009.
22	Melotte V, Lentjes MH, van den Bosch SM, et al: N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst. 101:916–927. 2009.
23	Lodish H, Baltimore D, Berk A, Zipursky SL, Mastudaira P and Darnell J: Molecular cell biology. 3rd Edition. Scientific American Books; New York, NY: 1995
24	Chen WD, Han ZJ, Skoletsky J, et al: Detection in fecal DNA of colon cancer-speciic methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. 97:1124–1132. 2005.